In contrast, Tregs from RA patients treated with IL-6 receptor inhibitors showed increased Treg migration when compared with untreated RA patients and healthy controls, as well as the ability to alter Treg migration via antibody-mediated GPSM2 inhibition. Here, GPSM2 is linked to rheumatoid arthritis.